1.56
-0.005(-0.32%)
Currency In USD
| Previous Close | 1.56 |
| Open | 1.56 |
| Day High | 1.57 |
| Day Low | 1.54 |
| 52-Week High | 3.35 |
| 52-Week Low | 1.14 |
| Volume | 7,487 |
| Average Volume | 365,031 |
| Market Cap | 23.11M |
| PE | -1.14 |
| EPS | -1.35 |
| Moving Average 50 Days | 1.38 |
| Moving Average 200 Days | 1.65 |
| Change | -0.02 |
If you invested $1000 in Longeveron Inc. (LGVN) since IPO date, it would be worth $20.78 as of July 30, 2025 at a share price of $1.54. Whereas If you bought $1000 worth of Longeveron Inc. (LGVN) shares 2 years ago, it would be worth $25.29 as of July 30, 2025 at a share price of $1.54.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease
GlobeNewswire Inc.
Jul 21, 2025 1:15 PM GMT
Joshua Hare Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Chairman, Longeveron Longeveron has licensed issued US Patent 12,168,028 B2, entitled “Methods for obtaining cardiomyogenic precursor cells” from the University of Mia
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)
GlobeNewswire Inc.
Jul 08, 2025 1:15 PM GMT
Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trialPhase 2 clinical trial initiation anticipated
Longeveron® Appoints Than Powell as Chief Business Officer
GlobeNewswire Inc.
Jun 26, 2025 1:05 PM GMT
Mr. Powell to oversee Longeveron’s partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for